ASGCT 2026 Day 2: PackGene Highlights AAV Process Optimization and Continued Industry Engagement

BOSTON, May 13^th, 2026  —

PackGene continued its strong presence on Day 2 of the 29th American Society of Gene & Cell Therapy Annual Meeting, engaging with researchers, biotech companies, pharmaceutical partners, and CDMO collaborators from around the world. From booth discussions to scientific presentations, the team shared PackGene’s latest progress in gene therapy vector development, AAV manufacturing, quality control, and innovative delivery technologies.

Throughout the day, Booth #1531 remained active with visitors interested in PackGene’s integrated platforms across AAV, mRNA/LNP, lentiviral vectors, and plasmid manufacturing. The discussions reflected a clear industry focus on practical development challenges, including AAV process scale-up, GMP manufacturing readiness, in vivo delivery vector development, analytical method establishment, and CMC strategies for clinical translation.

A key highlight of the day was PackGene’s oral presentation, “Advancing AAV Manufacturing through Process Optimization and Intensification,” delivered by Ran Li, Associate Director of Process & Analytic Development, in MCEC Room 258ABC. The presentation focused on critical challenges in AAV production and shared how PackGene is improving both upstream and downstream processes to enhance vector quality and manufacturing efficiency.

On the upstream side, the presentation discussed strategies such as high-cell-density transfection to increase volumetric productivity and support more efficient AAV scale-up. On the downstream side, PackGene highlighted purification optimization, including chromatography-based approaches to enrich full capsids and improve the overall quality profile of final AAV products. These process improvements are especially important as AAV programs increasingly require not only high yield, but also consistent quality, scalability, and regulatory readiness.

The presentation generated strong interest and technical discussion among attendees, underscoring the field’s growing need for robust, scalable, and high-quality AAV manufacturing solutions. As more gene therapy programs move from early discovery toward IND-enabling studies and clinical production, process intensification and product quality control are becoming central priorities across the industry.

PackGene’s Day 2 activities further demonstrated its role as an integrated CRO/CDMO partner for the global gene therapy community. With capabilities spanning vector design and construction, AAV production, lentiviral vector services, mRNA/LNP services, GMP plasmid manufacturing, analytical testing, and end-to-end CMC support, PackGene remains committed to helping partners advance gene therapy programs from concept to clinic.

Backed by its proprietary π-Alpha™ 293 AAV High-Yield Platform, PackGene continues to provide scalable solutions designed to support diverse research, clinical, and commercial project needs. As ASGCT 2026 continues, the PackGene team looks forward to further conversations, scientific exchange, and collaboration with partners working to advance the next generation of gene therapies.